UNCY Insider Trading

Insider Ownership Percentage: 40.90%
Insider Buying (Last 12 Months): $12,300.00
Insider Selling (Last 12 Months): $0.00

Unicycive Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Unicycive Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Unicycive Therapeutics Share Price & Price History

Current Price: $0.53
Price Change: +0.30 (1.20%)
As of 02/6/2023 01:00 AM ET

This chart shows the closing price history over time for UNCY up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Unicycive Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/16/2022Brigitte SchillerDirectorBuy15,000$0.82$12,300.0015,000View SEC Filing Icon  
See Full Table
The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Get the Name & Ticker Here

SEC Filings (Institutional Ownership Changes) for Unicycive Therapeutics (NASDAQ:UNCY)

6.43% of Unicycive Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at UNCY by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Unicycive Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/15/2022Board of Trustees of The Leland Stanford Junior University63,019$37K0.0%-74.5%0.419%Search for SEC Filing on Google Icon
11/10/2022Nantahala Capital Management LLC710,542$0.42M0.0%-2.6%4.721%Search for SEC Filing on Google Icon
8/15/2022Nantahala Capital Management LLC729,680$0.61M0.0%+13.9%4.855%Search for SEC Filing on Google Icon
5/13/2022Nantahala Capital Management LLC640,633$0.83M0.0%-6.7%4.265%Search for SEC Filing on Google Icon
4/22/2022Truist Financial Corp37,462$48K0.0%N/A0.250%Search for SEC Filing on Google Icon
11/12/2021Board of Trustees of The Leland Stanford Junior University247,583$0.70M0.1%N/A1.707%Search for SEC Filing on Google Icon
11/9/2021BlackRock Inc.11,443$33K0.0%N/A0.079%Search for SEC Filing on Google Icon
10/28/2021Tandem Capital Management Corp ADV15,500$44K0.0%N/A0.107%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Unicycive Therapeutics logo
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Read More on Unicycive Therapeutics

Today's Range

Now: $0.53
Low: $0.53
High: $0.57

50 Day Range

MA: $0.61
Low: $0.44
High: $0.75

52 Week Range

Now: $0.53
Low: $0.40
High: $1.64

Volume

266,119 shs

Average Volume

271,826 shs

Market Capitalization

$7.98 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.38

Who are the company insiders with the largest holdings of Unicycive Therapeutics?

Unicycive Therapeutics' top insider investors include:
  1. Brigitte Schiller (Director)
Learn More about top insider investors at Unicycive Therapeutics.